Teduglutide

A recombinant 33-amino-acid analog of glucagon-like peptide-2, engineered for DPP-4 resistance and FDA-approved in 2012 as Gattex, that reduces parenteral-support dependence in short bowel syndrome by expanding the gut's absorptive capacity.

Also referenced as: Gattex, Revestive, ALX-0600, SHP633

Also appears in: Metabolic

What is Teduglutide?

Teduglutide is a recombinant 33-amino-acid analog of human glucagon-like peptide-2 (GLP-2) in which the alanine at position 2 is replaced with glycine, a single substitution that protects the peptide from enzymatic degradation and stretches its half-life from a few minutes to roughly two hours. It was approved by the FDA in December 2012 as Gattex (Revestive in Europe) for adults with short bowel syndrome who depend on intravenous nutrition, with the indication extended to children one year and older in 2019 — making it one of the few compounds on the research-peptide market with a completed, successful Phase 3 program behind it.

The compound’s codes trace its corporate history: ALX-0600 comes from Allelix Biopharmaceuticals, which licensed the Gly2 analog work and was folded into NPS Pharmaceuticals, the company that carried the drug to approval; SHP633 from Shire, which acquired NPS in 2015 before itself being absorbed by Takeda. It circulates in the research-peptide market on “gut repair” and “leaky gut” framing, and on spillover interest from the GLP-1 weight-loss drugs — despite acting on an entirely different receptor system with no weight-loss evidence.

How it works

• GLP-2 receptor agonism. Teduglutide binds GLP-2 receptors located on intestinal enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons of the submucosal and myenteric plexuses; activation triggers local release of mediators including insulin-like growth factor 1, nitric oxide, and keratinocyte growth factor (FDA prescribing information for Gattex). The growth effect on the mucosa is therefore indirect — the receptor is not on the absorptive enterocytes themselves.
• Engineered DPP-4 resistance. Native GLP-2 is rapidly inactivated by dipeptidyl peptidase IV cleavage at the position-2 alanine; the Gly2 substitution renders the analog resistant to that cleavage and markedly increases its intestinotrophic potency in vivo (Drucker et al., Nature Biotechnology, 1997;15:673–677). This is the founding piece of chemistry that made a GLP-2 drug practical.
• Mucosal growth in humans. In a 21-day open-label study in short bowel syndrome patients, teduglutide increased villus height and crypt depth of the intestinal mucosa alongside improved intestinal wet-weight absorption — structural adaptation, not just a functional tweak (Jeppesen et al., Gut, 2005;54(9):1224–1231).
• Increased fluid and nutrient absorption. In clinical studies, teduglutide enhanced gastrointestinal fluid (wet-weight) absorption by approximately 750–1,000 mL/day (FDA prescribing information), which is the mechanism behind the approved endpoint: reducing how much intravenous fluid and nutrition a patient with a shortened bowel needs.

Research status

Teduglutide’s evidence base is deep by research-market standards, but it is concentrated almost entirely in one population: patients with short bowel syndrome and intestinal failure, whose remaining bowel is being pushed to compensate for what was surgically removed.

Pivotal trials. A first Phase 3 dose-ranging study randomized 83 parenteral-nutrition-dependent patients to teduglutide 0.05 mg/kg/day, 0.10 mg/kg/day, or placebo for 24 weeks; the lower dose met the primary graded-response endpoint against placebo while the higher dose did not — an inverted dose-response that is why the approved dose is the lower one (Jeppesen et al., Gut, 2011;60(7):902–914). The confirmatory STEPS trial (ClinicalTrials.gov NCT00798967) randomized 86 patients to 0.05 mg/kg/day or placebo for 24 weeks: 63% of teduglutide patients versus 30% on placebo achieved at least a 20% reduction in weekly parenteral support volume (p = 0.002), with mean reductions of about 4.4 L/week versus 2.3 L/week (Jeppesen et al., Gastroenterology, 2012;143(6):1473–1481).

Long-term extensions. The two-year open-label STEPS-2 extension reported that parenteral-support reductions continued to deepen with ongoing daily dosing, with 13 of 88 enrolled patients achieving full independence from intravenous support (Schwartz et al., Clinical and Translational Gastroenterology, 2016). A further extension, STEPS-3, followed a small group to roughly three and a half years of cumulative exposure with continued reductions and no new safety signals (Seidner et al., Nutrition in Clinical Practice, 2018).

Pediatrics. A 24-week Phase 3 study in children aged 1–17 with short bowel syndrome (NCT02682381) let families choose teduglutide or standard of care, randomizing only the blinded dose: 69% of children on 0.05 mg/kg/day and 54% on 0.025 mg/kg/day achieved at least a 20% reduction in parenteral support, against 11% of the standard-of-care group (Kocoshis et al., JPEN Journal of Parenteral and Enteral Nutrition, 2020;44(4):621–631), supporting the 2019 pediatric label extension.

The discontinued lane. An 8-week randomized, placebo-controlled pilot in moderate-to-severe Crohn’s disease reported numerically higher response and remission rates on every teduglutide dose, clearest — and apparent as early as week two — on the highest dose, where remission reached 32% versus 20% on placebo and response 44% versus 32% (Buchman et al., Inflammatory Bowel Diseases, 2010;16(6):962–973) — but the differences were never statistically demonstrated, the program was never advanced, and no approval exists outside short bowel syndrome. Newer GLP-2 analogs (apraglutide, glepaglutide) have since been developed by other sponsors for the same short-bowel indication, not for general gut health.

What does not exist: any controlled human trial of teduglutide in people with an intact, structurally normal gut. The “gut optimization” use case the research market implies has no clinical evidence behind it.

Common dosage forms

• Pharmaceutical kit (prescription). Gattex/Revestive is supplied as a single-dose vial of 5 mg lyophilized teduglutide packaged with 0.5 mL sterile water for reconstitution and subcutaneous injection.
• Research-market lyophilized vials, commonly labeled 5 mg or 10 mg, sold without diluent or delivery kit. These are synthetic copies of a product manufactured recombinantly for the pharmaceutical supply chain, and their identity and purity are not independently verifiable from the label.
• Multi-peptide “gut repair” stacks, where teduglutide appears alongside compounds such as BPC-157 or larazotide, sometimes without a separately stated per-vial quantity.

This section describes formats only and is not dosing guidance.

Key considerations

• The mechanism is growth promotion, and the label treats that as the central risk. Because teduglutide can accelerate the growth of existing gastrointestinal neoplasia, the FDA label requires a colonoscopy and upper-GI endoscopy (with polyp removal) within six months before starting, repeat evaluation after one year, then at least every five years, and discontinuation if gastrointestinal malignancy develops. A compound sold casually as “gut healing” carries, in its approved form, a mandatory cancer-surveillance schedule.
• It is not a GLP-1 drug. The “-glutide” suffix invites confusion with semaglutide and liraglutide, but teduglutide acts on the GLP-2 receptor: its effect is intestinal mucosal growth and absorption, with no weight-loss, appetite, or glycemic indication and no evidence for those uses.
• Every efficacy result comes from damaged-bowel patients. The trials enrolled people with surgically shortened intestines dependent on intravenous nutrition (plus one Crohn’s pilot). What supraphysiologic GLP-2 signaling does to a normal-length, healthy gut has simply not been studied in humans.
• The label’s other safety signals are substantial. Enhanced fluid absorption cuts both ways: in the placebo-controlled trials, peripheral edema occurred in 10% of teduglutide-treated patients versus 3% on placebo, with fluid overload and cases of congestive heart failure also observed. The label additionally flags biliary and pancreatic disease requiring laboratory monitoring every six months, intestinal obstruction, and — a direct consequence of the mechanism — potentially increased absorption of concomitant oral medications, with monitoring advised for drugs that require titration or have a narrow therapeutic index.
• Benefits accrued slowly and dose-response ran backward. Clinical responses built over months of continuous daily dosing, and in the dose-ranging Phase 3 the 0.05 mg/kg dose met its endpoint while double that dose did not — a reminder that “more” was not better even in the population the drug was designed for.